FDA — authorised 7 July 2022
- Application: ANDA212198
- Marketing authorisation holder: ZYDUS PHARMS
- Local brand name: EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE
- Indication: TABLET — ORAL
- Status: approved
FDA authorised EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE on 7 July 2022
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA authorised it on 7 July 2022; FDA has authorised it; FDA has authorised it.
ZYDUS PHARMS holds the US marketing authorisation.